SPORTS MEDICINE
Benefit of BM-MSC addition in core decompression in treatment of osteonecrosis of the femoral head
Int J Surg. 2019 Jul 10;69:23-3114 randomized controlled trials were included in this meta-analysis which sought to investigate the impact of autologous bone marrow-derived mesenchymal stem cell (MSC) administration alongside core decompression on outcomes in treatment of patients with osteonecrosis of the femoral head. Pooled analyses of pain scores from 6 months to 2 years, function from 1 to 2 years, and incidence of eventual total hip arthroplasty, ranging from 1 to 5 years in the same analysis, all significantly favoured MSC groups compared to control groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
